Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
SAN FRANCISCO, CA and TOKYO, JAPAN – September 10, 2014 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (Tokyo: 4503) announced today that the U.S. Food and Drug Administration...
Pfizer Japan Inc. (Tokyo, “Pfizer”) and Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced that the companies have agreed to terminate the distribution and co-promotion...
Tokyo, August 29, 2014 - Astellas Pharma Inc. (“Astellas”; TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka), today announced that it has pledged donations of 3 million yen...
Read more about Astellas Pharma Supports to Flood Relief Efforts in Western Japan
Cancer Research UK and its commercial arm, Cancer Research Technology (“CRT”), are to join forces with Astellas Pharma Inc. (Tokyo, President & CEO: Yoshihiko Hatanaka, “Astellas”) to find...
Tokyo, July 14, 2014 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that it submitted a supplemental new drug application for the...
Astellas today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for isavuconazole for the treatment of invasive aspergillosis...
Tokyo, Japan, 25 June, 2014 – Astellas Pharma Inc. (“Astellas”; TSE:4503, headquarters: Chuo-ku, Tokyo; president and CEO: Yoshihiko Hatanaka) and UCB Japan Co., Ltd. (“UCB Japan”;...
Follow us
